Final ID: Su3154
Jiang Chao, Dong Jianzeng, Cai Jun, Anderson Craig, Du Xin, Tang Yangyang, Han Rong, Song Yanna, Wang Chi, Lin Xiaolei, Yi Yang, Rodgers Anthony, Ma Changsheng
37,500 man-years of clinical expertise validate the cardio-metabolic benefits of empagliflozin-linagliptin in type 2 diabetes: findings from the amplified consensusNair Tiny, Jabbar P, Ray Saumitra, Hazra Prakash, Gupta Sushil, Joshi Ameya, Shaikh Shehla, B Jayagopal, Pandit Kaushik, Sharma D, Seshadri Krishna, S Sridhar